Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

42.96 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Data support the Company’s lead investigational product candidate sparsentan 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Travere Therapeutics ↗
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Travere Therapeutics to Report Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA ↗
 
Via Benzinga
News headline image
Expert Ratings for Travere Therapeutics ↗
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings: 
Via Benzinga
News headline image
FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease ↗
 
Via Benzinga
News headline image
Travere Therapeutics Return On Capital Employed Overview ↗
  
Via Benzinga
News headline image
121 Stocks That Hit Their 52-Week Low ↗
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Recap: Travere Therapeutics Q2 Earnings ↗
  Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Where Travere Therapeutics Stands With Analysts ↗
Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market ↗
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
News headline image
Analyst Ratings for Travere Therapeutics ↗
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug ↗
The FDA will review Travere's drug by mid-November for a kidney disease. 
Via Investor's Business Daily
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗
 
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication ↗
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
4 Analysts Have This to Say About Travere Therapeutics ↗
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion. 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know ↗
HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5%... 
Via Benzinga
News headline image
FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review ↗
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of... 
Via Benzinga
News headline image
Here's Why Travere Therapeutics Shares Are Rising Today ↗
Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million. 
Via Benzinga
News headline image
Earnings Outlook For Retrophin ↗
Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will... 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.